Searchable abstracts of presentations at key conferences in endocrinology

ea0026p288 | Pituitary | ECE2011

Pegvisomant therapy in acromegaly: a multicenter observational study

Bianchi A , Tilaro L , Valentini F , Gargiulo P , Poggi M , Baldelli R , Passeri M , De Marinis L

Patients with acromegaly resistant to conventional drug treatment currently can advantage with GH-receptor antagonist pegvisomant. To date, at doses up to 40 mg/day, it is capable of normalizing circulating IGF1 in until 97% of patients. Here we present the multicenter experience in Rome with Pegvisomant as a therapeutic option in acromegaly. This is an observational study including a total of 61 patients (21 males and 40 females) treated with pegvisomant for up to 7 years. Of...

ea0011p546 | Endocrine tumours and neoplasia | ECE2006

Cell proliferation and outcome of GH-secreting pituitary adenomas

De Marinis L , Bianchi A , Tilaro L , Doglietto F , Veltri F , Vellone GV , Lugli F , Fusco A , Cimino V , Pontecorvi A , Lauriola L

In order to investigate the correlations between immunohistochemical picture with proliferative index (Ki-67), the clinical course and outcome of GH-secreting pituitary adenomas not cured by neurosurgery, we studied 41 consecutive acromegalic patients (M 12, F 29; aged 43±10.8 yr) previously undergone neurosurgical resection of adenoma. Two patients underwent neurosurgical intervention at least twice. Post-surgical follow-up ranged from 6 to 36 months and all patients rec...

ea0020p550 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

Bianchi Antonio , Mazziotti Gherardo , Tilaro Laura , Cimino Vincenzo , Porcelli Teresa , Mormando Marilda , Tartaglione Linda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-G...